578 related articles for article (PubMed ID: 23992515)
1. Tiotropium Respimat inhaler and the risk of death in COPD.
Wise RA; Anzueto A; Cotton D; Dahl R; Devins T; Disse B; Dusser D; Joseph E; Kattenbeck S; Koenen-Bergmann M; Pledger G; Calverley P;
N Engl J Med; 2013 Oct; 369(16):1491-501. PubMed ID: 23992515
[TBL] [Abstract][Full Text] [Related]
2. The Tiotropium Safety and Performance in Respimat® (TIOSPIR®) Trial: Spirometry Outcomes.
Anzueto A; Wise R; Calverley P; Dusser D; Tang W; Metzdorf N; Dahl R
Respir Res; 2015 Sep; 16(1):107. PubMed ID: 26369563
[TBL] [Abstract][Full Text] [Related]
3. The efficacy of tiotropium administered via Respimat Soft Mist Inhaler or HandiHaler in COPD patients.
van Noord JA; Cornelissen PJ; Aumann JL; Platz J; Mueller A; Fogarty C
Respir Med; 2009 Jan; 103(1):22-9. PubMed ID: 19022642
[TBL] [Abstract][Full Text] [Related]
4. Effect of switching tiotropium HandiHaler® to Respimat® Soft Mist™ Inhaler in patients with COPD: the difference of adverse events and usability between inhaler devices.
Asakura Y; Nishimura N; Maezawa K; Terajima T; Kizu J; Chohnabayashi N
J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):41-5. PubMed ID: 22691112
[TBL] [Abstract][Full Text] [Related]
5. Tiotropium 5microg via Respimat and 18microg via HandiHaler; efficacy and safety in Japanese COPD patients.
Ichinose M; Fujimoto T; Fukuchi Y
Respir Med; 2010 Feb; 104(2):228-36. PubMed ID: 19969446
[TBL] [Abstract][Full Text] [Related]
6. Tiotropium HandiHaler(®) and Respimat(®) in COPD: a pooled safety analysis.
Halpin DM; Dahl R; Hallmann C; Mueller A; Tashkin D
Int J Chron Obstruct Pulmon Dis; 2015; 10():239-59. PubMed ID: 25709423
[TBL] [Abstract][Full Text] [Related]
7. Use of tiotropium Respimat Soft Mist Inhaler versus HandiHaler and mortality in patients with COPD.
Verhamme KM; Afonso A; Romio S; Stricker BC; Brusselle GG; Sturkenboom MC
Eur Respir J; 2013 Sep; 42(3):606-15. PubMed ID: 23520322
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of tiotropium in patients switching from HandiHaler to Respimat in the TIOSPIR trial.
Dahl R; Calverley PM; Anzueto A; Metzdorf N; Fowler A; Mueller A; Wise R; Dusser D
BMJ Open; 2015 Dec; 5(12):e009015. PubMed ID: 26715479
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of combining olodaterol Respimat(®) and tiotropium HandiHaler(®) in patients with COPD: results of two randomized, double-blind, active-controlled studies.
ZuWallack R; Allen L; Hernandez G; Ting N; Abrahams R
Int J Chron Obstruct Pulmon Dis; 2014; 9():1133-44. PubMed ID: 25342898
[TBL] [Abstract][Full Text] [Related]
10. A randomized study of tiotropium Respimat Soft Mist inhaler vs. ipratropium pMDI in COPD.
Voshaar T; Lapidus R; Maleki-Yazdi R; Timmer W; Rubin E; Lowe L; Bateman E
Respir Med; 2008 Jan; 102(1):32-41. PubMed ID: 17996436
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of the efficacy and safety of tiotropium bromide (5 µg) inhaled via Respimat in Chinese patients with chronic obstructive pulmonary disease.
Tang Y; Massey D; Zhong NS
Chin Med J (Engl); 2013; 126(19):3603-7. PubMed ID: 24112149
[TBL] [Abstract][Full Text] [Related]
12. The Tiotropium Safety and Performance in Respimat Trial (TIOSPIR), a large scale, randomized, controlled, parallel-group trial-design and rationale.
Wise RA; Anzueto A; Calverley P; Dahl R; Dusser D; Pledger G; Koenen-Bergmann M; Joseph E; Cotton D; Disse B
Respir Res; 2013 Apr; 14(1):40. PubMed ID: 23547660
[TBL] [Abstract][Full Text] [Related]
13. Comparative mortality risk of tiotropium administered via handihaler or respimat in COPD patients: are they equivalent?
Mathioudakis AG; Chatzimavridou-Grigoriadou V; Evangelopoulou E; Mathioudakis GA; Siafakas NM
Pulm Pharmacol Ther; 2014 Aug; 28(2):91-7. PubMed ID: 24846455
[TBL] [Abstract][Full Text] [Related]
14. Questionnaire on switching from the tiotropium HandiHaler to the Respimat inhaler in patients with chronic obstructive pulmonary disease: changes in handling and preferences immediately and several years after the switch.
Hanada S; Wada S; Ohno T; Sawaguchi H; Muraki M; Tohda Y
Int J Chron Obstruct Pulmon Dis; 2015; 10():69-77. PubMed ID: 25609941
[TBL] [Abstract][Full Text] [Related]
15. Tiotropium Respimat(®) Versus HandiHaler(®): Comparison of Bronchodilator Efficacy of Various Doses in Clinical Trials.
Calverley PM; Könen-Bergmann M; Richard F; Bell S; Hohlfeld JM
Adv Ther; 2016 May; 33(5):786-93. PubMed ID: 27084728
[TBL] [Abstract][Full Text] [Related]
16. TIOtropium Safety and Performance In Respimat
Zhong N; Moon HS; Lee KH; Mahayiddin AA; Boonsawat W; Isidro MG; Bai C; Mueller A; Metzdorf N; Anzueto A
Respirology; 2016 Nov; 21(8):1397-1403. PubMed ID: 27490162
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of the once-daily anticholinergic BEA2180 compared with tiotropium in patients with COPD.
Abrahams R; Moroni-Zentgraf P; Ramsdell J; Schmidt H; Joseph E; Karpel J
Respir Med; 2013 Jun; 107(6):854-62. PubMed ID: 23490224
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials.
Decramer M; Anzueto A; Kerwin E; Kaelin T; Richard N; Crater G; Tabberer M; Harris S; Church A
Lancet Respir Med; 2014 Jun; 2(6):472-86. PubMed ID: 24835833
[TBL] [Abstract][Full Text] [Related]
19. Seasonal variations in exacerbations and deaths in patients with COPD during the TIOSPIR
Wise RA; Calverley PM; Carter K; Clerisme-Beaty E; Metzdorf N; Anzueto A
Int J Chron Obstruct Pulmon Dis; 2018; 13():605-616. PubMed ID: 29497289
[TBL] [Abstract][Full Text] [Related]
20. Tiotropium versus placebo for chronic obstructive pulmonary disease.
Karner C; Chong J; Poole P
Cochrane Database Syst Rev; 2012 Jul; (7):CD009285. PubMed ID: 22786525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
